NCCN Guidelines® Insights - Melanoma, Version 4.2014

The NCCN Guidelines for Melanoma provide multidisciplinary recommendations on the management of patients with melanoma. These NCCN Guidelines Insights highlight notable recent updates. Dabrafenib and trametinib, either as monotherapy (category 1) or combination therapy, have been added as systemic options for patients with unresectable metastatic melanoma harboring BRAF V600 mutations. Controversy continues regarding the value of adjuvant radiation for patients at high risk of nodal relapse. This is reflected in the category 2B designation to consider adjuvant radiation following lymphadenectomy for stage III melanoma with clinically positive nodes or recurrent disease.

Target Audience

This activity has been designated to meet the educational needs of physicians, nurses, and pharmacists involved in the management of patients with cancer.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Integrate into professional practice the updates to NCCN Guidelines for Melanoma
  • Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Melanoma
Additional information
Supporters: 

Supported by an independent educational grant from Prometheus Laboratories Inc., and by an education grant from Exelixis, Inc., and by educational grants from Bayer HealthCare, Onyx Pharmaceuticals, Inc., and Algeta US; Genentech; Genomic Health, Inc.; NOVOCURE; and Merck Sharp & Dohme Corp.

Course summary
Available credit: 
  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Pharmacist
  • 1.00 Physician
Course opens: 
05/09/2014
Course expires: 
05/09/2015
Cost:
$0.00

Available Credit

  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Pharmacist
  • 1.00 Physician

Accreditation Period

Course opens: 
05/09/2014
Course expires: 
05/09/2015

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To access this activity, users will need:

  • A device with an Internet connection
  • Adobe Reader or other PDF reader software for article and certificate viewing/printing